Quantcast
Last updated on April 18, 2014 at 14:46 EDT

Debiopharm and Yale Announce an Exclusive License Agreement for the Development and Commercialization of Debio 1036, a First-in-Class Inhibitor for Autoimmune and Inflammatory Diseases

May 4, 2011

LAUSANNE, Switzerland and NEW HAVEN, Connecticut, May 4, 2011
/PRNewswire/ — Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical
development specialist that focuses on serious medical conditions and
particularly oncology, and Yale University (Yale), a premier university with
a long tradition of both basic and clinically directed biomedical research,
announce an exclusive worldwide license agreement concerning the development
and commercialization of Debio 1036, a first-in-class inhibitor for
autoimmune and inflammatory diseases.

“We are very excited about this new collaboration with Yale. Their
leadership in marrying chemistry and biology to identify and validate lead
drug candidates has yielded a new approach to treating inflammatory disease.
The Debio 1036 project aims at developing inhibitors targeting a fundamental
inflammatory pathway, which plays essential roles in myriad diseases
progression and severity,” said Dr Rolland-Yves Mauvernay, president and
founder of Debiopharm S.A.

Yale is delighted to be partnered with Debiopharm to advance this
program through the pre-clinical and clinical development process. The
relationship with Debiopharm is a stellar example of the complementarities
between academic discovery and commercial development. This discovery is
further evidence of the valuable contributions academic institutions can make
on behalf of patients. We sincerely believe this agreement represents the
beginning of a long and fruitful relationship between Yale and Debiopharm for
both Debio 1036 and other programs at Yale,” added Richard C. Levin, Yale
University
President.

The agreement between Yale and Debiopharm anticipates the need for global
access to medicines.

About Debio 1036

Debio 1036 is an orally available small molecule that antagonizes a key
mediator in the inflammation process. This therapeutically important target
is unique in several ways due to its action early on in the inflammatory
cascade and its ability to regulate cell growth and apoptosis.

About Debiopharm Group

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global
biopharmaceutical group of companies with a focus on the development of
prescription drugs that target unmet medical needs. The group in-licenses,
develops and/or co-develops promising biological and small molecule drug
candidates having reached clinical development phases I, II or III as well as
earlier stage candidates. It develops its products for global registration
and maximum commercial potential. The products are out-licensed to
pharmaceutical partners for sales and marketing. Debiopharm Group is also
active in the field of companion diagnostics with a view to progressing in
the area of personalized medicine. Debiopharm independently funds the
worldwide development of all of its products while providing expertise in
pre-clinical and clinical trials, manufacturing, drug delivery and
formulation, and regulatory affairs. For more information on Debiopharm
Group(TM), please visit: http://www.debiopharm.com .

About Yale University

Founded in 1701, Yale University comprises three major academic
components: Yale College (the undergraduate program), the Graduate School of
Arts and Sciences, and the professional schools. Founded in 1810, Yale School
of Medicine
is a world-renowned center for biomedical research, education and
advanced healthcare. Yale School of Medicine consistently ranks among the
handful of leading recipients of research funding from the National
Institutes of Health and other organizations supporting the biomedical
sciences. Its core faculty of more than 1,100 physicians and scientists is
well represented within the Institute of Medicine and National Academy of
Sciences and among investigators of the Howard Hughes Medical Institute. In
addition, Yale encompasses a wide array of centers and programs, libraries,
museums, and administrative support offices. Approximately 11,250 students
attend Yale. For more information on Yale University, please visit:
http://www.yale.edu/

    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs & communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com

    Additional Media Contacts

    In London
    Maitland
    Brian Hudspith
    Tel.: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel.: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com

    Yale Contact
    William Hathaway
    Associate Director of Media
    Tel.: +1-203-432-1322
    william.hathaway@yale.edu

SOURCE The Debiopharm Group


Source: newswire